Diabetes Research and Clinical Practice
Volume 88, Issue 1 , Pages 42-47 , April 2010

Effects of short-term therapy with different insulin secretagogues on glucose metabolism, lipid parameters and oxidative stress in newly diagnosed Type 2 Diabetes Mellitus

  • Yan Li

      Affiliations

    • Department of Endocrinology and Metabology, Sun Yat-Sen Memorial Hospital, 107th Yanjiang Western Road, Guangzhou 510120, China
    • Corresponding Author InformationCorresponding author. Tel.: +86 20 81332286; fax: +86 20 81332404.
    • ,
  • Lijuan Xu

      Affiliations

    • Department of Endocrinology and Metabology, The Sixth Affiliated Hospital of Sun Yat-Sen University, Memorial Hospital, 107th Yanjiang Western Road, Guangzhou 510120, China
    • ,
  • Jie Shen

      Affiliations

    • Department of Endocrinology and Metabology, Southern Hospital, Guangzhou, China
    • ,
  • Jianmin Ran

      Affiliations

    • Department of Endocrinology and Metabology, Guangzhou Red Cross Hospital, Guangzhou, China
    • ,
  • Yang Zhang

      Affiliations

    • Department of Endocrinology and Metabology, Guangzhou Red Cross Hospital, Guangzhou, China
    • ,
  • Min Wang

      Affiliations

    • Department of Endocrinology and Metabology, Southern Hospital, Guangzhou, China
    • ,
  • Li Yan

      Affiliations

    • Department of Endocrinology and Metabology, Sun Yat-Sen Memorial Hospital, 107th Yanjiang Western Road, Guangzhou 510120, China
    • ,
  • Hua Cheng

      Affiliations

    • Department of Endocrinology and Metabology, Sun Yat-Sen Memorial Hospital, 107th Yanjiang Western Road, Guangzhou 510120, China
    • ,
  • Zuzhi Fu

      Affiliations

    • Department of Endocrinology and Metabology, Sun Yat-Sen Memorial Hospital, 107th Yanjiang Western Road, Guangzhou 510120, China

Received 25 May 2009 ,Revised 18 November 2009 ,Accepted 14 December 2009.

References 

  1. Stamler J, Vaccaro O, Newton JD, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the multiple risk factor interventional trial. Diabetes Care. 1993;16:434–444
  2. UK Prospective Diabetes Study (UKPDS) Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  3. Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation effects of short- and long-term simvastatin treatment. Circulation. 2002;106:1211–1218
  4. Mori Y, Kitahara Y, Miura K, Mine T, Tajima N. Role of early insulin secretion in postglucose-loading hyperglycaemia and postfat-loading hyperlipidaemia: comparing nateglinide and glibenclamide for acute effects on insulin secretion in OLETF rats. Diabetes Obes. Metab. 2004;6:422–431
  5. Kabadi MU, Kabadi UM. Effects of glimepiride on insulin secretion and sensitivity in patients with recently diagnosed type 2 diabetes mellitus. Clin. Ther. 2004;6:63–69
  6. Korytkowski M, Thomas A, Reid L, Tedesco MB, Gooding WE, Gerich J. Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes. Diabetes Care. 2002;25:1607–1611
  7. Clark HE, Matthews DR. The effect of glimepiride on pancreatic B-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus. Horm. Metab. Res. 1996;28:445–450
  8. Juhl CB, Pørksen N, Pincus SM, Hansen AP, Veldhuis JD, Schmitz O. Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes. Diabetes. 2001;50:1778–1784
  9. Derosa G, Mugellini A, Ciccarelli L, Crescenzi G, Fogari R. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. Clin. Ther. 2003;25(13):472–484
  10. Cesur M, Corapcioglu D, Gursoy A, Gonen S, Ozduman M, Emral R, et al. A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting. Diabetes Res. Clin. Pract. 2007;75(2):141–147
  11. Singhal P, Caumo A, Cobelli C, Taylor R. Effect of repaglinide and gliclazide on postprandial control of endogenous glucose production. Metabolism. 2005;54(1):79–84
  12. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295:1681–1687
  13. Schmitz O, Lund S, Andersen PH, Jønler M, Pørksen N. Optimizing insulin secretagogue therapy in patients with type 2 diabetes, a randomized double-blind study with repaglinide. Diabetes Care. 2002;25:342–346
  14. Owens DR, Cozma LS, Luzio SD. Early-phase prandial insulin secretion: its role in the pathogenesis of type 2 diabetes mellitus and its modulation by repaglinide. Diabetes Nutr. Metab. 2002;15:19–27
  15. Vibeke H. Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin. Pharmacokinet. 2002;41(7):471–483
  16. Culy CR, Jarvis B. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. Drugs. 2001;61:1625–1660
  17. Hollingdal M, Sturis J, Gall MA, Damsbo P, Pincus S, Veldhuis JD, et al. Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in type 2 diabetes. Diabet. Med. 2005;22:1408–1413
  18. Nappo F, Esposito K, Cioffi M, Giugliano G, Molinari AM, Paolisso G, et al. Postprandial endothelial function in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J. Am. Coll. Cardiol. 2002;39:1145–1150
  19. Sampson MJ, Gopaul N, Davies IR, Hughes DA, Carrier MJ. Plasma F2 isoprostanes: direct evidence of increased free radical damage during acute hyperglycemia in type 2 diabetes. Diabetes Care. 2002;25:537–541
  20. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, et al. Activation of oxidative stress by acute glucose fluctuation compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295:1681–1687
  21. Gumieniczek A. Effects of repaglinide on oxidative stress in tissues of diabetic rabbits. Diabetes Res. Clin. Pract. 2005;68:89–95
  22. Tina KS, Gunnar HG, Rigs Ho, Søren R, Casper HJ, Fredrik F, et al. Differences in risk of cardiovascular death according to type of oral glucose-lowering therapy in patients with diabetes: a nationwide study. In: The 69th Scientific Sessions of ADA, June 5–9. New Orleans, Louisiana. 2009;p. 1–2

PII: S0168-8227(09)00542-7

doi: 10.1016/j.diabres.2009.12.017

Diabetes Research and Clinical Practice
Volume 88, Issue 1 , Pages 42-47 , April 2010

Article Tools

* Image Usage & Resolution